title: Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.
abstract: We screened a panel of R5X4 and X4 human immunodeficiency virus type 1 (HIV-1) strains for their sensitivities to AMD3100, a small-molecule CXCR4 antagonist that blocks HIV-1 infection via this coreceptor. While no longer under clinical development, AMD3100 is a useful tool with which to probe interactions between the viral envelope (Env) protein and CXCR4 and to identify pathways by which HIV-1 may become resistant to this class of antiviral agents. While infection by most virus strains was completely blocked by AMD3100, we identified several R5X4 and X4 isolates that exhibited plateau effects: as the AMD3100 concentration was increased, virus infection and membrane fusion diminished to variable degrees. Once saturating concentrations of AMD3100 were achieved, further inhibition was not observed, indicating a noncompetitive mode of viral resistance to the drug. The magnitude of the plateau varied depending on the virus isolate, as well as the cell type used, with considerable variation observed when primary human T cells from different human donors were used. Structure-function studies indicated that the V1/V2 region of the R5X4 HIV-1 isolate DH12 was necessary for AMD3100 resistance and could confer this property on two heterologous Env proteins. We conclude that some R5X4 and X4 HIV-1 isolates can utilize the AMD3100-bound conformation of CXCR4, with the efficiency being influenced by both viral and host factors. Baseline resistance to this CXCR4 antagonist could influence the clinical use of such compounds.
authors.affiliation: Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
authors.forename: Jessamina E
authors.initials: JE
authors.lastname: Harrison
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Lynch
authors.forename: Luz-Jeannette
authors.initials: LJ
authors.lastname: Sierra
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Blackburn
authors.forename: Neelanjana
authors.initials: N
authors.lastname: Ray
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Collman
authors.forename: Robert W
authors.initials: RW
authors.lastname: Doms
mesh_terms: D000818:Animals; D001596:Benzylamines; D002478:Cells, Cultured; D000080027:Cyclams; D024882:Drug Resistance, Viral; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D011784:Quail; D019713:Receptors, CCR5 / Q000737:chemistry; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000737:chemistry
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D015699:HIV Envelope Protein gp120; D023581:HIV Fusion Inhibitors; D006571:Heterocyclic Compounds; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; C514793:gp120 protein, Human immunodeficiency virus 1; C088327:plerixafor
references.citation: J Leukoc Biol. 2006 Nov;80(5):965-72
references.pmid: 16923919
references.citation: Nat Rev Drug Discov. 2003 Jul;2(7):581-7
references.pmid: 12815382
references.citation: Nat Med. 1996 Jul;2(7):760-6
references.pmid: 8673921
references.citation: J Virol. 2007 Apr;81(7):3240-50
references.pmid: 17251281
references.citation: J Virol. 2004 Aug;78(16):8654-62
references.pmid: 15280474
references.citation: J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62
references.pmid: 15385732
references.citation: J Virol. 2001 Jun;75(12):5457-64
references.pmid: 11356952
references.citation: Curr Top Microbiol Immunol. 2006;303:97-120
references.pmid: 16570858
references.citation: Nature. 1996 Nov 14;384(6605):184-7
references.pmid: 8906796
references.citation: AIDS. 2001 Sep 7;15(13):1627-34
references.pmid: 11546936
references.citation: Science. 2002 Jun 28;296(5577):2354-60
references.pmid: 12089434
references.citation: Virology. 2004 Oct 10;328(1):74-88
references.pmid: 15380360
references.citation: Antimicrob Agents Chemother. 1997 Dec;41(12):2616-20
references.pmid: 9420029
references.citation: J Virol. 2005 Feb;79(3):1480-6
references.pmid: 15650174
references.citation: Methods Enzymol. 1997;288:118-33
references.pmid: 9356991
references.citation: AIDS. 2001 Sep 7;15(13):1671-7
references.pmid: 11546942
references.citation: Biochem Pharmacol. 2006 Aug 28;72(5):588-96
references.pmid: 16815309
references.citation: AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26
references.pmid: 15000703
references.citation: Virology. 2001 Mar 15;281(2):239-47
references.pmid: 11277696
references.citation: J Virol. 1998 May;72(5):4478-84
references.pmid: 9557745
references.citation: J Virol. 2004 Jul;78(14):7582-9
references.pmid: 15220433
references.citation: Nat Med. 1998 Jan;4(1):72-7
references.pmid: 9427609
references.citation: Cell. 1999 Mar 5;96(5):667-76
references.pmid: 10089882
references.citation: J Exp Med. 1997 Oct 20;186(8):1383-8
references.pmid: 9334378
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54
references.pmid: 12444251
references.citation: J Virol. 2004 Mar;78(6):2790-807
references.pmid: 14990699
references.citation: J Virol. 2007 Sep;81(18):9956-66
references.pmid: 17609282
references.citation: PLoS Pathog. 2006 Feb;2(2):e10
references.pmid: 16485036
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
references.pmid: 10220446
references.citation: J Virol. 2003 Jan;77(2):1610-3
references.pmid: 12502877
references.citation: Cell. 1996 Nov 15;87(4):745-56
references.pmid: 8929542
references.citation: J Virol. 1995 Jul;69(7):4453-62
references.pmid: 7769705
references.citation: Antiviral Res. 1997 Aug;35(3):147-56
references.pmid: 9298754
references.citation: J Virol. 2008 Jan;82(2):664-73
references.pmid: 17977968
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11360-5
references.pmid: 9736741
references.citation: J Virol. 2005 Apr;79(7):4347-56
references.pmid: 15767435
references.citation: J Virol. 2005 Nov;79(21):13250-61
references.pmid: 16227248
references.citation: Virology. 2007 Aug 1;364(2):281-90
references.pmid: 17428518
references.citation: J Antimicrob Chemother. 2006 Apr;57(4):619-27
references.pmid: 16464888
references.citation: J Virol. 1996 Feb;70(2):689-96
references.pmid: 8551604
references.citation: J Virol. 1999 Sep;73(9):7117-25
references.pmid: 10438797
references.citation: Virology. 2007 May 25;362(1):163-78
references.pmid: 17239419
references.citation: Antimicrob Agents Chemother. 1994 Apr;38(4):668-74
references.pmid: 7913308
references.citation: PLoS Pathog. 2007 Aug 24;3(8):e117
references.pmid: 17722977
references.citation: J Virol. 2000 Jan;74(2):693-701
references.pmid: 10623731
references.citation: J Cell Biol. 2000 Oct 16;151(2):413-23
references.pmid: 11038187
references.citation: J Virol. 2003 Dec;77(24):13042-52
references.pmid: 14645561
references.citation: J Neurovirol. 2004;10 Suppl 1:91-6
references.pmid: 14982745
references.citation: J Exp Med. 1997 May 5;185(9):1681-91
references.pmid: 9151905
references.citation: J Clin Invest. 1999 Sep;104(5):R7-R11
references.pmid: 10487781
references.citation: Science. 2007 Sep 28;317(5846):1930-4
references.pmid: 17901336
references.citation: Virology. 2005 Jul 20;338(1):182-99
references.pmid: 15935415
references.citation: J Virol. 1997 Apr;71(4):3219-27
references.pmid: 9060685
references.citation: AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1715-24
references.pmid: 11788023
references.citation: J Virol. 2007 Mar;81(5):2359-71
references.pmid: 17182681
references.citation: J Virol. 1998 Mar;72(3):2509-15
references.pmid: 9499115
references.citation: AIDS Res Hum Retroviruses. 2005 Feb;21(2):171-89
references.pmid: 15725757
references.citation: Virology. 2007 Apr 25;361(1):212-28
references.pmid: 17166540
references.citation: J Virol. 1992 May;66(5):2934-42
references.pmid: 1560532
references.citation: J Virol. 1996 Oct;70(10):7318-21
references.pmid: 8794390
references.citation: Lancet. 2007 Jul 7;370(9581):81-8
references.pmid: 17617275